Biotech Pulse: NIH Grant Disputes, FDA Openness, and Rising M&A Activity
Navigating Legal Challenges to NIH Funding
Recent investigations reveal a concerning trend: the National institutes of Health (NIH) is employing a specific legal strategy to justify the termination of research grants. An internal memo obtained by STAT,details the framework being utilized by the Department of Health and Human Services (HHS) to support these cuts. This disclosure arrives amidst escalating legal battles questioning the validity of these funding reductions, with multiple cases currently being contested in court. The core of the dispute centers around the NIH’s interpretation of budgetary constraints and the impact of restrictions related to Diversity, Equity, and Inclusion (DEI) initiatives. As of July 2025, restoring previously cut grants is proving complex, further complicated by the limitations imposed by court orders.
FDA Transparency: A Qualified Advance
The Food and Drug Management (FDA) Commissioner Marty Makary recently initiated the publication of hundreds of letters sent to pharmaceutical companies regarding rejected drug applications. While presented as a move towards greater transparency in the drug review process, critics point out a notable limitation: the released letters pertain only to drugs that were ultimately approved. This selective disclosure diminishes the value of the details, as it doesn’t offer insight into the reasons for outright rejections. Furthermore, Commissioner Makary has yet to commit to releasing “complete response letters” – the full documentation detailing rejections – for drugs denied approval during his tenure. This raises questions about the extent of the FDA’s commitment to truly open and extensive review practices. The current landscape suggests a nuanced approach to transparency, rather than a fully open system.
Biotech M&A Heats Up: Merck’s Acquisition of Verona Pharma
The biotechnology sector is witnessing a surge in mergers and acquisitions (M&A) activity, driven by established pharmaceutical companies seeking to replenish their pipelines and secure future revenue streams. A prime example is Merck’s recent announcement of its intent to acquire Verona Pharma for $10 billion. This acquisition is particularly significant as it focuses on Verona’s expertise in lung disease treatments. With key patents on blockbuster drugs like Keytruda facing expiration, large pharma companies are aggressively pursuing innovative therapies to offset potential revenue losses. The Merck-Verona deal underscores a broader trend: a competitive market where established players are investing heavily in biotech innovation to maintain market leadership. According to recent analysis, biotech M&A volume in the first half of 2025 has already surpassed the total for the same period last year, indicating a sustained period of consolidation.
stay Informed:
For in-depth coverage of the NIH grant terminations, see https://www.statnews.com/2025/07/06/hhs-nih-grant-terminations-legal-guidance-internal-memo/ and https://www.statnews.com/2025/07/03/nih-cuts-grant-restoration-complicated-by-limits-to-court-order-trump-dei-restrictions/. Explore STAT’s reporting on the FDA: https://www.statnews.com/topic/fda/.
* Read more about the Merck-Verona Pharma deal: https://www.statnews.com/2025/07/09/merck-verona-pharma-lung-disease-keytruda-patent-protection-losses/.
Listen to the Discussion:
For a deeper dive into these topics, tune into “The readout LOUD” podcast on Apple Podcasts or Spotify.